HomeComparePTE vs MRK

PTE vs MRK: Dividend Comparison 2026

PTE yields 20912.86% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PTE wins by $81743643826372870144.00M in total portfolio value
10 years
PTE
PTE
● Live price
20912.86%
Share price
$0.24
Annual div
$50.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$81743643826372870144.00M
Annual income
$80,981,894,292,535,550,000,000,000.00
Full PTE calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — PTE vs MRK

📍 PTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTE
Annual income on $10K today (after 15% tax)
$1,777,593.43/yr
After 10yr DRIP, annual income (after tax)
$68,834,610,148,655,210,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, PTE beats the other by $68,834,610,148,655,210,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTE + MRK for your $10,000?

PTE: 50%MRK: 50%
100% MRK50/50100% PTE
Portfolio after 10yr
$40871821913186435072.00M
Annual income
$40,490,947,146,267,780,000,000,000.00/yr
Blended yield
99.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PTE
Analyst Ratings
8
Buy
5
Hold
1
Sell
Consensus: Buy
Price Target
$1.00
+314.9% upside vs current
Range: $1.00 — $1.00
Altman Z
-44.1
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTE buys
0
MRK buys
0
No recent congressional trades found for PTE or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTEMRK
Forward yield20912.86%2.76%
Annual dividend / share$50.40$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$81743643826372870144.00M$56.8K
Annual income after 10y$80,981,894,292,535,550,000,000,000.00$9,798.13
Total dividends collected$81693400766216093696.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$1.00$128.54

Year-by-year: PTE vs MRK ($10,000, DRIP)

YearPTE PortfolioPTE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,101,986$2,091,286.39$11,206$366.19+$2.09MPTE
2$413,076,745$410,827,619.58$12,650$502.35+$413.06MPTE
3$75,895,025,125$75,453,033,007.71$14,407$694.19+$75895.01MPTE
4$13,037,343,348,491$12,956,135,671,607.02$16,585$967.82+$13037343.33MPTE
5$2,093,969,922,274,026$2,080,019,964,891,140.80$19,342$1,363.89+$2093969922.25MPTE
6$314,463,669,699,286,140$312,223,121,882,452,900.00$22,913$1,947.19+$314463669699.26MPTE
7$44,157,379,181,838,770,000$43,820,903,055,260,530,000.00$27,662$2,823.89+$44157379181838.74MPTE
8$5,798,076,105,195,996,000,000$5,750,827,709,471,428,000,000.00$34,159$4,173.35+$5798076105195996.00MPTE
9$711,915,452,184,400,000,000,000$705,711,510,751,840,300,000,000.00$43,337$6,308.80+$711915452184400000.00MPTE
10$81,743,643,826,372,860,000,000,000$80,981,894,292,535,550,000,000,000.00$56,776$9,798.13+$81743643826372870144.00MPTE

PTE vs MRK: Complete Analysis 2026

PTEStock

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Full PTE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PTE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTE vs SCHDPTE vs JEPIPTE vs OPTE vs KOPTE vs MAINPTE vs JNJPTE vs ABBVPTE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.